ASCO Updates Treatment Guidelines for Advanced NSCLC

August 15, 2017 – ASCO has updated its guidelines for first- and second-line treatment of patients with stage IV non–small cell lung cancer (NSCLC). The organization has created new recommendations regarding the use of immunotherapy, and updated advice on targeted therapies for patients with mutations in the EGFR, ALK, or ROS1 genes. “Treatment for lung cancer has become increasingly more complex over the last several years,” Nasser Hanna, MD, co-chair … (leggi tutto)